The treatment for glaucoma has come a long way. Today’s advanced technologies and procedures make it possible to diagnose and successfully manage this progressive disease. And while the overall goal of treatment has always remained the same — reducing intraocular pressure (IOP) and glaucomatous progression — Micro-Invasive Glaucoma Surgery (MIGS) is quickly becoming a widely accepted approach for treating mild-to-moderate glaucoma.
Glaucoma Therapy Advances
Glaucoma is primarily managed with prescription eye drops. If a patient’s glaucoma progresses or the patient stops responding to the eye drops, a surgical solution is offered. These surgical solutions are often highly invasive, require long recovery times, and could result in long-term complications.
glaucoma surgery. This opened more surgical options for patients interested in effective glaucoma management which does not rely solely on the continuous use of prescription medication.
A Revolution in Glaucoma Therapy
With the FDA approval of the iStent®, Micro-Invasive Glaucoma Surgery (MIGS) became a preferred approach to glaucoma management for many eye care professionals and their patients with mild-to-moderate glaucoma.
Now, with the FDA approval of iStent inject® – the next-generation Glaukos trabecular micro-bypass technology – Glaukos is advancing the standard of care for glaucoma patients.
Performed at the time of cataract surgery, iStent inject® has proven to be effective in decreasing IOP, with an excellent safety profile, few complications, and fast recovery time.
iStent inject® may also reduce patients’ need for medications as determined by an eye care professional. The majority of patients who received iStent inject® in the U.S. pivotal trial were medication-free at 23 months.
2 Other benefits associated with this innovative treatment include:
- Minimally traumatic to delicate eye tissue
- Effectively lowers IOP
- Excellent safety profile
- Rapid recovery